Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Recruitment of Second Patient for HG-CT-1 Clinical Trial
LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant step forward in the Company's clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.
The manufacturing of HG-CT-1 for the second patient, carried out by the Company's team of scientists and quality control professionals, is scheduled to commence shortly.
Further updates on the clinical trial will be provided in due course.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
'The recruitment of the second patient is indicative of the promising results of the clinical trial for HG-CT-1 thus far and represents another critical step in advancing HG-CT-1 as a potential breakthrough treatment for relapsed or refractory AML. This milestone reflects the dedication of our team and the strength of our science, bringing us closer to addressing an urgent unmet medical need.'
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Dairy is so back. It's now a high-protein, gut-healthy superfood shoppers love.
Want to snack on something that's high in protein, gut-friendly, minimally processed, and tastes good? Hit the dairy aisle. After years of being outshone and relegated to second best by shiny, new plant-based alternatives like oat milk and cashew cream, dairy is not only in demand, it's having a glow-up. Products like mint chocolate cookie probiotic ice cream and pistachio-flavored kefir — some of which come wrapped in whimsical, retro-style packaging — are hitting the market as dairy finds itself at the center of the Venn diagram of health, food, and cultural trends. "I really have not seen this type of dairy innovation in past years," Jessica Rubino of New Hope Network, an organic-focused consultancy firm that tracks US food and drink industry trends, told Business Insider. According to the organization's insights, the organic dairy sector grew by 9.8% in 2024, up from 5.6% the previous year — far higher than the one or two percent a year increase seen since around 2015. "That type of increase in growth is pretty significant," Rubino said. Dairy aligns with health trends With 82% of US consumers considering wellness a top or important priority in their everyday lives, according to 2024 trend data from McKinsey, food and drink can't just taste good, it needs to provide health benefits too. A large part of dairy's appeal right now is that it's high in protein and minimally processed. Whether you want to eat enough protein to build muscle, you use a GLP-1 and need more protein to maintain muscle mass or are a member of the manosphere following the carnivore diet, we've gone protein-crazy in recent years. The global protein market is estimated to reach over $47.4 billion by 2032, up from $26 billion in 2021, according to Statista. Protein-enhanced products, such as sodas, waters, powders, and bars, have taken over grocery store aisles. Fairlife, the industry leader in ultra-filtered milk, which contains 50% more protein than regular milk, has seen dollar sales rise by 31% in the past 12 months, according to data from market research agency Circana. The milk is filtered to separate its components (water, lactose, protein, fat, and vitamins and minerals) and reformulated. Lactose and sugar are removed, and protein is concentrated. Melissa Altobelli, a dairy industry analyst at Circana, told BI that Fairlife, which has been around since 2012, has exploded in popularity recently because its product chimes with current trends. "It's not that the effort wasn't made in the past. It's just more appealing to consumers currently," she said, adding: "Protein is in everything at this point, and that's what consumers are looking for." Rubino also sees gut health as a particularly big draw for dairy, as people seek out functional foods to "optimize" their health and live longer. "You can get high dosages of probiotics through these food products," she said. The ultra-processed foods backlash is good news for dairy As ultra-processed foods take over from carbs as the demon of the dietary world, shoppers are losing their appetite for them. Typically long-lasting and designed to be irresistible and easy to eat, these foods contain ingredients you wouldn't find in a regular kitchen, such as gums, emulsifiers, and colors. Mounting research links ultra-processed foods to a host of health conditions — from type 2 diabetes to depression and poor gut health. As public awareness of ultra-processed foods has grown, people have become more wary of alt milks, which typically contain additives, Amy Bentley, a professor of food studies at NYU who specializes in the American diet, told BI. "Alt meat and alt milk don't want to be put in that category. They want to say, 'Hey, we're different.' But if you read those ingredient labels of some of those alt products, they are very, very ultra processed," she said. This has been dairy's gain: "The pendulum has swung back," Andrea Hernández, the author of the food trends newsletter Snaxshot, told BI. "Milk was the original functional drink," Hernández said, "and it's become culturally cool again." "Consumers are still looking for simple ingredients and naturalness," Altobelli said. And traditional dairy products, like unflavored yogurts and cottage cheese, as well as more innovative ones like Fairlife, fit the bill. The cult status of raw dairy in a MAHA world Dairy products, including raw milk, have become part of a cultural conversation in the past year or so. Fans of raw milk say it contains more beneficial microbes than pasteurized milk and can protect against allergies and asthma. Food scientists, however, argue that the ostensible benefits of raw milk are outweighed on a population level by the risk of catching bird flu or being poisoned by E. coli. Raw milk, along with beef tallow and butter, has also become synonymous with the "make America healthy again," or MAHA, movement. Its spearhead, Robert F. Kennedy Jr, the US Health Secretary, said in June 2024 that he only drinks raw milk and, before he was appointed, criticized what he called the FDA's "aggressive suppression" of raw milk, which he said on X in October 2024 "advances human health." In late May, he took shots of the stuff in the White House on a podcast. Federal law prohibits the sale of raw milk across state lines, but individual state laws, not the FDA, dictate whether it can be sold within that state. Raw milk enthusiasts include people across the political and cultural spectrum. Republican congresswoman Marjorie Taylor Greene posted "Raw Milk does a body good" on X in October 2024. Gwyneth Paltrow, an early adopter of wellness culture, said she adds raw milk creamer to her coffee every morning. And "tradwife" influencer and dairy farmer Hannah Neeleman, who posts as "Ballerina Farm" online, was featured milking one of her cows on the cover of the conservative women's magazine Evie in November, emblazoned with the words " The New American Dream." Hernández said there is a "romanticization of a dairy farm or a farmer's life." "It's become trendy to be able to say, 'Oh, I got this $20 raw milk jug at Erewhon,'" the Los Angeles-based health food store known for its $20 smoothies, she said. The next era for dairy: exotic flavors with health benefits People may want their meals to be nutritious, but that doesn't mean they're willing to compromise on taste. On top of wellness, consumers, and Gen Z in particular, are looking for "unusual flavors as they seek new and unique experiences," according to branding consultancy and market research agency VML's Future 100: 2025 trends report. One in four of us want "interesting and exotic global flavor combinations," the report said. If the offerings at Natural Products Expo West, a prolific trade show for organic, sustainable food and beverage products, which took place in California in March, are any indication, brands are meeting the moment. Attendees could try ashwagandha -infused or Aleppo chile-flavored ghee, pineapple cottage cheese, and reduced-sugar chai tea-flavored yogurt. Alec's, an organic ice cream brand that displayed at the trade show, launched their Culture Cup, a 4 fl oz cup of ice cream with added pre- and probiotics, in April with flavors including chocolate-covered strawberry and dark chocolate honeycomb. All Things Butter, a company founded by the British chef Thomas Straker in 2023, has also gained traction for its flavored butters. Current products include cinnamon bun butter, chocolate butter, and smoked paprika butter. Unlike traditional butter packaging, its butter sticks come in colorful foil adorned with anthropomorphic cartoon cows. It was the first "very yassified, very millennial looking" dairy brand Hernández noticed, but she's certain we'll see many more.
Yahoo
4 hours ago
- Yahoo
Here are the forecasts for Tesco shares out to 2028
Tesco (LSE: TSCO) shares have gained 35% over the past five years, though the price has been a bit volatile along the way. Pressure on the retail sector has had an effect on Tesco in recent times. But against that, investors often see companies selling essentials as safe havens in times of stock market uncertainty. Tesco has held on to its market-leading position as number one in the UK groceries business. In fact, the latest Kantar survey showed market share actually growing to 28%. Tesco seems to be holding off the threat of competition from cheapies like Aldi and Lidl nicely enough. We're increasingly seeing price competition creeping back to our high streets again. So what's the outlook like for Tesco in the current year and beyond? A first-quarter trading update due on 12 June will give us an idea how the current year is starting out. At 2024/25 results time, the company told us it expects adjusted operating profit for the 2025/26 year within a range of £2.7bn to £3.0bn. That's a little below the £3,128m in the year just ended, and reflects 'a further increase in the competitive intensity of the UK market' seen in the first few months of the year. Currently, broker forecasts show that turning into earnings per share (EPS) of around 26p. That would be approximately 12% ahead of the 23.13p diluted EPS figure reported for 2024/25. Maybe it's a bit optimistic considering the company's own outlook? It can sometimes take months for broker updates to feed through. City analysts expect earnings to grow to 32p per share by 2028. And that would be an impressive 38% rise in just three years. They must surely have factored several optimistic possibilities into that. Interest rates should fall further in the next three years. Where their new steady level will be remains to be seen, but I can't see us getting back close to those lovely old 0.5% levels for quite a long time. I think it would also need today's US-led trade wars to settle down, and for the economic growth outlook to get back to strength. Will those both happen by 2028? Maybe I'm an optimist, but I put my investment money on it however long it takes. Do I think we should consider buying Tesco now, on the back of these upbeat forecasts? Well, I can't remember a time when I haven't had Tesco down as a candidate buy on my list. Every time I have money to invest though, I seem to find something I like better. I'm still bullish, as always. We're looking at a forward price-to-earnings (P/E) ratio of around 14.5, very close to the FTSE 100 average. And it could drop to 12 by 2028 if the analysts have it right. With valuations like that, and dividend yields of around 3.5%, I can understand why Tesco shares hold a cornerstone position in so many Stocks and Shares ISAs. I'm considering finally adding some to mine. The post Here are the forecasts for Tesco shares out to 2028 appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended Tesco Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
5 hours ago
- Business Insider
Wizz Air Holdings (WIZZ) Receives a Hold from Kepler Capital
In a report released on June 5, Marc Zeck from Kepler Capital maintained a Hold rating on Wizz Air Holdings (WIZZ – Research Report), with a price target of p1,600.00. The company's shares closed yesterday at p1,174.00. Confident Investing Starts Here: Zeck covers the Industrials sector, focusing on stocks such as Kuehne + Nagel International AG, DHL Group, and DSV A/S. According to TipRanks, Zeck has an average return of 13.3% and a 70.97% success rate on recommended stocks. In addition to Kepler Capital , Wizz Air Holdings also received a Hold from J.P. Morgan's Harry Gowers in a report issued yesterday. However, on June 5, Bernstein maintained a Buy rating on Wizz Air Holdings (LSE: WIZZ). Based on Wizz Air Holdings' latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of p1.81 billion and a net profit of p317.7 million. In comparison, last year the company earned a revenue of p1.82 billion and had a net profit of p344 million Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of WIZZ in relation to earlier this year.
